The Global Cell-Free DNA (cfDNA) testing Market size was valued at USD 3.80 Billion in 2019 and is anticipated to reach USD 22.41 Billion by 2027 at a CAGR of 26.2%. The increased maternal age, lifestyle changes, and unhealthy diet habits have increased the incidence of diseases like chromosomal abnormalities, which is expected to boost the global Cell-Free DNA (cfDNA) testing market growth during the forecast period.
The latest research report by Emergen Research, named ‘Global Cell-Free DNA (cfDNA) Testing Market - Forecast to 2027’, entails a comprehensive review of the global Cell-Free DNA (cfDNA) Testing market’s present and future trends. The report gathers viable information on the most established industry players, sales and distribution channels, regional spectrum, estimated market share and size, and revenue estimations over the forecast timeframe.
Get a sample of the report @https://www.emergenresearch.com/request-sample/156
Market Scope:
One of the report’s central components is the broad Cell-Free DNA (cfDNA) Testing market segmentation that includes the product type gamut, application spectrum, end-user industry landscape, significant geographical regions, and the top market contenders. The report contains unbiased industry expert opinions on the current market scenario, past market performance, production & consumption rates, demand & supply ratio, and revenue generation forecasts over the estimated period. The key players’ financial positions, along with their gross profits, sales volumes, sales revenue, manufacturing costs, and other financial ratios, have been accurately gauged in the report.
Top Key Players:
- Sequenom, Inc.
- Quest Diagnostics
- Illumina Inc.
- Agilent Technologies, Inc.
- Guardant Health, Inc.
- Biodesix, Inc.
- Allenex AB
- Roche Holdings AG
- Biocept, Inc.
- CareDx, Inc.
Regional Overview:
- North America (U.S., Canada)
- Europe (U.K., Italy, Germany, France, Rest of EU)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Get access to the full description of the report @ https://www.emergenresearch.com/industry-report/cell-free-dna-market
Thank you for reading the report. The report can be customized as per the requirements of the clients. For further information or query about customization, please reach out to us, and we will offer you the report best suited for your needs.
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: [email protected]
Global cell-free DNA testing market was valued US$ 85.3 Mn in 2017 and is expected to reach US$ 439.2 Mn by 2026, at a CAGR of 22.73 % during a forecast period.
The non-invasive prenatal test is a new technology being used to assess the risk of a pregnant woman's and taking a sample of blood from the vein rather than inserting a needle into the uterus similar to amniocentesis.
The cell-free DNA testing is used in many fields such as gynecology, oncology, and transplantation to identify mutations in cancer patients and identify various chromosomal abnormalities in the fetus, to know the gender of the fetus.
Health damaging lifestyle actions such as the increased use of tobacco & alcohol, lack of physical activity, poor eating habits or heavy consumption of fast foods, are the major driving factors for chronic diseases.
The growth of cell-free fetal DNA testing market is mainly expected to exact and effective results for aneuploidy screening.
Down syndrome is generally caused by an error in cell division called “nondisjunction.” It caused when abnormal cell division results in extra genetic material from chromosome 21.
The increasing demand for non-invasive testing methodologies and rising chronic disease incidence are driving the demand for the market.The global Cell-Free DNA (cfDNA) Testing Market is forecasted to be worth USD 22.41 Billion by 2027, according to a new report by Emergen Research.
The global Cell-Free DNA (cfDNA) testing market is expected to grow significantly during the forecast period due to the increased incidence of cancers, rising prevalence of chromosome abnormalities in babies due to an increasing number of late pregnancy, and growing demand for non-invasive testing procedures.
Besides, the increasing investments by governments to implement advanced therapeutic technology in hospitals is also expected to boost the market during the forecast period.The research offers a bird’s eye view of the current market scenario regarding the operations of the leading companies in the Cell-Free DNA Testing market.
The report presents an extensive analysis of the leading players with regards to their business portfolio, product portfolio, market share and size, global reach and position, revenue share, gross profit margins, and production and manufacturing capacity.Download the report description @ https://www.emergenresearch.com/request-sample/156 Radical Highlights of the Cell-Free DNA Testing Market Report:Study of the latest product launches and technological advancements to help the readers in formulating investment strategiesFocus on market scenario, dynamics, and trends to be expected in the coming yearsAdvanced analytical tools such as Porter’s Five Forces analysis, SWOT analysis, feasibility analysis, and investment return analysisThorough regional analysis to offer insights into production and consumption patterns, supply and demand ratio, market size, revenue contrition, and the presence of prominent playersCompetitive landscape benchmarking with a focus on business profiles, product portfolio, business strategies such as M activities, revenue, market positions, market share, global position, and financial standingKey participants include Sequenom, Inc., Quest Diagnostics, Illumina Inc., Agilent Technologies, Inc., Guardant Health, Inc., Biodesix, Inc., Allenex AB, Roche Holdings AG, Biocept, Inc., and CareDx, Inc., among others.Covid AnalysisThe research report draws focus on the impact of the COVID-19 pandemic on the market and its crucial segments.
It offers insights into the effects of the pandemic on the global economic scenario and business sphere.
The report evaluates the key market influencing factors and considers the COVID-19 pandemic as one of the contributing elements.Financial difficulties brought by the pandemic have slowed down the progression of the businesses, and disruptions in the supply chains have been seen.
